Somsubhra Nath
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Somsubhra Nath has a total of 163 co-authors. Here are the top co-authors by number of shared publications:
Susanta Roychoudhury
CSIR-Indian Institute of Chemical Biology (TRUE Campus), Kolkata, India
7 shared publicationsStuti Roy
Basic and Translational Research Division, Saroj Gupta Cancer Centre and Research Institute (SGCC & RI), Kolkata 700063, India
5 shared publications- Susanta Roychoudhury
Cancer Biology and Inflammatory Disorder Division, CSIR-Indian Institute of Chemical Biology, Kolkata, India
5 shared publications - Susanta Roychoudhury
Cancer Biology and Inflammatory Disorder Division CSIR‐Indian Institute of Chemical Biology Kolkata India
5 shared publications - Kishor K. Bhakat
Department of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, NE 68198, USA
4 shared publications - Mainak Sengupta
Department of Genetics, University of Calcutta, Kolkata, India.
4 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1910442
Editorial: Novel approaches to overcome drug resistance in breast cancer
Modality or one mechanism of resistance. Instead, they include cellular plasticity, subtypespecific therapeutic innovation, predictive biomarker development, experimental target discovery, optimization of treatment strategies, and supportive-care interventions to maintain therapeutic benefit. The editorial pulls together papers on these various dimensions and therefore offers a contemporary perspective on resistance research as an interdisciplinary enterprise that demands coordination across molecular biology, pathology, imaging, clinical trial design, and supportive oncology. Within this broader framework, one of the central discussions of the editorial is the review on epithelial-to-mesenchymal transition (EMT) and its role in breast cancer drug resistance. The importance of this contribution is that it attempts to re-position EMT as more than a process associated with invasion and metastasis. Rather, EMT is framed as a form of cellular plasticity that allows tumor cells to respond to therapeutic pressure and persist through treatment (1,2). The editorial states that the review's key contribution is "to systematically integrate EMTassociated signaling pathways, transcription factors and microRNA networks, thereby positioning resistance as a dynamic adaptive state rather than a fixed molecular defect." This view is particularly relevant as it includes the increasing acceptance that resistant tumor cells do not simply acquire a single dominant mutation but rather may transition into altered phenotypic states that offer more extensive survival advantages under endocrine, chemotherapeutic or targeted therapy. This EMT-centric review is considered a conceptual anchor for the collection as it addresses a process that covers a range of therapeutic contexts. And in doing so, emphasizes a critical paradigm shift in cancer biology: the move away from static models of resistance towards a more nuanced appreciation of hybrid states, lineage flexibility and context-dependent adaptation. At the same time, the editorial takes a measured stance on the review's translational implications. EMT remains a heterogeneous and controversial concept with the relative importance of partial EMT states debated and the difficulty in translating preclinical mechanistic insights into clinically validated therapeutic strategies. Overall, the review's main value lies in clarifying the biological concepts of resistance and suggesting possible therapeutic directions, rather than offering immediate clinical solutions.Another dimension of the Research Topic is reflected in the review of therapeutic innovations in triple-negative breast cancer (TNBC), a subtype that remains one of the most clinically aggressive and treatment-refractory forms of breast cancer (3)(4)(5). We bring this article in this editorial as an important reminder that TNBC should no longer be viewed as a receptornegative category defined by the absence of endocrine and HER2 targets. Rather it is now better conceptualised as a biologically heterogeneous disease with multiple candidate vulnerabilities. The review includes targeted pathways, such as androgen receptor signaling, PI3K/AKT/mTOR, Notch, Wnt/β-catenin, Hedgehog, and TGF-β. This way it provides a broad map of the changing therapeutic landscape to the readers and demonstrates how TNBC research is moving beyond the historical dependence on cytotoxic chemotherapy alone.The editorial highlights in particular the translational relevance of combining molecular targeting with monoclonal antibody-based strategies. This convergence reflects an emerging trend in the management of TNBC, where selective pathway inhibition, immune engagement, and microenvironmental modulation are increasingly being considered in concert, rather than in isolation. Thus, the strength of the article is its presentation of TNBC as a changing therapeutic landscape with a growing armamentarium of biologically based interventions. But the editorial also notes an important caveat: the clinical readiness of these strategies varies widely. Some are already supported by meaningful translational data, while others are still exploratory. So, the review is most successful as a broad overview of therapeutic diversification rather than a definitive guide to resistance management for standard of care. Nonetheless, it provides a valuable addition to the collection as it places drug resistance in the context of the rapidly evolving landscape of TNBC therapy.Among the original research articles, the work on circWWC3 and pathological complete response (pCR) after neoadjuvant therapy in TNBC stands out as one of the most directly translational contributions. Its significance is the integration of molecular biomarker assessment with immune and imaging factors to develop a predictive nomogram for treatment response. In particular, the study integrates circWWC3 expression, tumor-infiltrating lymphocytes, and diffusion parameters obtained from MRI, thus demonstrating a multimodal approach for response prediction. Given the inability of any single biomarker in isolation to adequately address the complexity of therapeutic sensitivity in TNBC, the editorial is correct to see this as an important avenue for breast cancer research.The real notability of this study lies in its layered approach. By blending molecular clues with imaging data, it paints a far richer picture of how triple-negative breast cancer responds to treatment than any single factor ever could. The discovery that high levels of circWWC3 might predict which patients will respond well to therapy is particularly exciting, hinting at a future where we could tailor treatments more precisely (6). That said, the authors wisely pump the brakes: these findings are still early, and we'll need rigorous testing across different patient groups before this becomes a go-to tool in the clinic. For now, circWWC3 looks more like a promising signpost than a proven driver of treatment...
- 1 October 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1910442
Open AccessEditorial: Novel approaches to overcome drug resistance in breast cancer
Modality or one mechanism of resistance. Instead, they include cellular plasticity, subtypespecific therapeutic innovation, predictive biomarker development, experimental target discovery, optimization of treatment strategies, and supportive-care interventions to maintain therapeutic benefit. The editorial pulls together papers on these various dimensions and therefore offers a contemporary perspective on resistance research as an interdisciplinary enterprise that demands coordination across molecular biology, pathology, imaging, clinical trial design, and supportive oncology. Within this broader framework, one of the central discussions of the editorial is the review on epithelial-to-mesenchymal transition (EMT) and its role in breast cancer drug resistance. The importance of this contribution is that it attempts to re-position EMT as more than a process associated with invasion and metastasis. Rather, EMT is framed as a form of cellular plasticity that allows tumor cells to respond to therapeutic pressure and persist through treatment (1,2). The editorial states that the review's key contribution is "to systematically integrate EMTassociated signaling pathways, transcription factors and microRNA networks, thereby positioning resistance as a dynamic adaptive state rather than a fixed molecular defect." This view is particularly relevant as it includes the increasing acceptance that resistant tumor cells do not simply acquire a single dominant mutation but rather may transition into altered phenotypic states that offer more extensive survival advantages under endocrine, chemotherapeutic or targeted therapy. This EMT-centric review is considered a conceptual anchor for the collection as it addresses a process that covers a range of therapeutic contexts. And in doing so, emphasizes a critical paradigm shift in cancer biology: the move away from static models of resistance towards a more nuanced appreciation of hybrid states, lineage flexibility and context-dependent adaptation. At the same time, the editorial takes a measured stance on the review's translational implications. EMT remains a heterogeneous and controversial concept with the relative importance of partial EMT states debated and the difficulty in translating preclinical mechanistic insights into clinically validated therapeutic strategies. Overall, the review's main value lies in clarifying the biological concepts of resistance and suggesting possible therapeutic directions, rather than offering immediate clinical solutions.Another dimension of the Research Topic is reflected in the review of therapeutic innovations in triple-negative breast cancer (TNBC), a subtype that remains one of the most clinically aggressive and treatment-refractory forms of breast cancer (3)(4)(5). We bring this article in this editorial as an important reminder that TNBC should no longer be viewed as a receptornegative category defined by the absence of endocrine and HER2 targets. Rather it is now better conceptualised as a biologically heterogeneous disease with multiple candidate vulnerabilities. The review includes targeted pathways, such as androgen receptor signaling, PI3K/AKT/mTOR, Notch, Wnt/β-catenin, Hedgehog, and TGF-β. This way it provides a broad map of the changing therapeutic landscape to the readers and demonstrates how TNBC research is moving beyond the historical dependence on cytotoxic chemotherapy alone.The editorial highlights in particular the translational relevance of combining molecular targeting with monoclonal antibody-based strategies. This convergence reflects an emerging trend in the management of TNBC, where selective pathway inhibition, immune engagement, and microenvironmental modulation are increasingly being considered in concert, rather than in isolation. Thus, the strength of the article is its presentation of TNBC as a changing therapeutic landscape with a growing armamentarium of biologically based interventions. But the editorial also notes an important caveat: the clinical readiness of these strategies varies widely. Some are already supported by meaningful translational data, while others are still exploratory. So, the review is most successful as a broad overview of therapeutic diversification rather than a definitive guide to resistance management for standard of care. Nonetheless, it provides a valuable addition to the collection as it places drug resistance in the context of the rapidly evolving landscape of TNBC therapy.Among the original research articles, the work on circWWC3 and pathological complete response (pCR) after neoadjuvant therapy in TNBC stands out as one of the most directly translational contributions. Its significance is the integration of molecular biomarker assessment with immune and imaging factors to develop a predictive nomogram for treatment response. In particular, the study integrates circWWC3 expression, tumor-infiltrating lymphocytes, and diffusion parameters obtained from MRI, thus demonstrating a multimodal approach for response prediction. Given the inability of any single biomarker in isolation to adequately address the complexity of therapeutic sensitivity in TNBC, the editorial is correct to see this as an important avenue for breast cancer research.The real notability of this study lies in its layered approach. By blending molecular clues with imaging data, it paints a far richer picture of how triple-negative breast cancer responds to treatment than any single factor ever could. The discovery that high levels of circWWC3 might predict which patients will respond well to therapy is particularly exciting, hinting at a future where we could tailor treatments more precisely (6). That said, the authors wisely pump the brakes: these findings are still early, and we'll need rigorous testing across different patient groups before this becomes a go-to tool in the clinic. For now, circWWC3 looks more like a promising signpost than a proven driver of treatment...
- Open Access
- 19 June 2026
- Published by Springer Nature in Research Square
Regulatory SH3-SH2 domain mutations in BCR–ABL1 drive imatinib resistance and confer dasatinib sensitivity in chronic myeloid leukemia
Selection of second-line tyrosine kinase inhibitor (TKI) in chronic myeloid leukemia (CML) is largely guided by kinase domain (KD) mutations in BCR::ABL1; however, a substantial subset of imatinib-resistant cases (~ 40%) lack targetable KD alterations, limiting therapeutic stratification. Given the critical role of the Src homology 2 (SH2) and SH3 domains in regulating BCR::ABL1 activity, we investigated regulatory domain mutations in a cohort of CML with clinically-validated front-line imatinib resistance. Deep sequencing identified a de novo mutation pair, located in SH2 (Y167H) and SH3 (T117P) domain, in 16% cases. Following this, structure-guided molecular dynamics simulations indicated this mutation pair to destabilize the imatinib-compatible BCR::ABL1 conformation, resulting in reduced inhibitor engagement. Likewise, in vitro and in vivo experiments corroborated this non-responsiveness to imatinib. In contrast, computational and experimental analyses identified dasatinib as an effective second-line agent, restoring drug sensitivity despite the regulatory domain perturbations. Case studies further supported the efficacy of dasatinib in overcoming resistance associated with these mutations. Importantly, detection of this mutation pair in an independent validation set underscores the relevance of regulatory domain alterations as a previously under-recognized mechanism of TKI resistance. These findings advocate for routine interrogation of BCR::ABL1 regulatory domains to refine therapeutic decision-making in imatinib-refractory CML.
- 19 June 2026
- Published by Springer Nature in Research Square
Open AccessRegulatory SH3-SH2 domain mutations in BCR–ABL1 drive imatinib resistance and confer dasatinib sensitivity in chronic myeloid leukemia
Selection of second-line tyrosine kinase inhibitor (TKI) in chronic myeloid leukemia (CML) is largely guided by kinase domain (KD) mutations in BCR::ABL1; however, a substantial subset of imatinib-resistant cases (~ 40%) lack targetable KD alterations, limiting therapeutic stratification. Given the critical role of the Src homology 2 (SH2) and SH3 domains in regulating BCR::ABL1 activity, we investigated regulatory domain mutations in a cohort of CML with clinically-validated front-line imatinib resistance. Deep sequencing identified a de novo mutation pair, located in SH2 (Y167H) and SH3 (T117P) domain, in 16% cases. Following this, structure-guided molecular dynamics simulations indicated this mutation pair to destabilize the imatinib-compatible BCR::ABL1 conformation, resulting in reduced inhibitor engagement. Likewise, in vitro and in vivo experiments corroborated this non-responsiveness to imatinib. In contrast, computational and experimental analyses identified dasatinib as an effective second-line agent, restoring drug sensitivity despite the regulatory domain perturbations. Case studies further supported the efficacy of dasatinib in overcoming resistance associated with these mutations. Importantly, detection of this mutation pair in an independent validation set underscores the relevance of regulatory domain alterations as a previously under-recognized mechanism of TKI resistance. These findings advocate for routine interrogation of BCR::ABL1 regulatory domains to refine therapeutic decision-making in imatinib-refractory CML.
- Open Access
- 21 May 2026
- Published by Springer Nature in Research Square
Promoter Hypermethylation and Androgen Receptor Regulation Unveil Dual Oxidase 1 as a Tumor Suppressor in Prostate Adenocarcinoma
Promoter hypermethylation of tumor suppressor genes (TSGs) is a hallmark of prostate cancer (PCa) development and holds promise as a diagnostic and prognostic biomarker. Through global methylation analysis of benign prostatic hyperplasia and PCa tissue samples, we identified dual oxidase 1 (DUOX1), a member of the NADPH oxidase family, as a methylation-driven TSG involved in PCa progression. Elevated DUOX1 expression is associated with improved disease-free and progression-free survival in PCa patients, emphasising its clinical relevance. Mechanistically, we show that de novo DNA methyltransferases (DNMT) -3A and -3B mediate DUOX1 promoter-hypermethylation, while the androgen receptor (AR) represses DUOX1 transcription by forming a negative chromosomal circuit through an enhancer-bound AR-H3K27ac-BRD4 axis. Genetic perturbations or pharmacological interventions with demethylating agents, anti-androgen therapies, or BET inhibitors relieve this repression, leading to increased DUOX1 expression. Functional restoration of DUOX1 in AR-positive PCa cells exhibited strong anti-proliferative and anti-metastatic effects by enhancing extracellular ROS production and reducing AR expression. Furthermore, DUOX1 re-expression selectively activated the cellular glucuronidation pathway, disrupting androgen signalling. Collectively, our findings establish DUOX1 as a methylation-driven, AR-regulated tumor suppressor and a promising biomarker for early diagnosis and targeted therapy in prostate adenocarcinoma.
- 21 May 2026
- Published by Springer Nature in Research Square
Open AccessPromoter Hypermethylation and Androgen Receptor Regulation Unveil Dual Oxidase 1 as a Tumor Suppressor in Prostate Adenocarcinoma
Promoter hypermethylation of tumor suppressor genes (TSGs) is a hallmark of prostate cancer (PCa) development and holds promise as a diagnostic and prognostic biomarker. Through global methylation analysis of benign prostatic hyperplasia and PCa tissue samples, we identified dual oxidase 1 (DUOX1), a member of the NADPH oxidase family, as a methylation-driven TSG involved in PCa progression. Elevated DUOX1 expression is associated with improved disease-free and progression-free survival in PCa patients, emphasising its clinical relevance. Mechanistically, we show that de novo DNA methyltransferases (DNMT) -3A and -3B mediate DUOX1 promoter-hypermethylation, while the androgen receptor (AR) represses DUOX1 transcription by forming a negative chromosomal circuit through an enhancer-bound AR-H3K27ac-BRD4 axis. Genetic perturbations or pharmacological interventions with demethylating agents, anti-androgen therapies, or BET inhibitors relieve this repression, leading to increased DUOX1 expression. Functional restoration of DUOX1 in AR-positive PCa cells exhibited strong anti-proliferative and anti-metastatic effects by enhancing extracellular ROS production and reducing AR expression. Furthermore, DUOX1 re-expression selectively activated the cellular glucuronidation pathway, disrupting androgen signalling. Collectively, our findings establish DUOX1 as a methylation-driven, AR-regulated tumor suppressor and a promising biomarker for early diagnosis and targeted therapy in prostate adenocarcinoma.
- Open Access
- 30 September 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1)
A signature of correlated CDC20 and UBCH10 expression indicates poor prognosis in primary head and neck squamous cell carcinoma
The orchestration of mitotic checkpoint execution depends on the enzymatic activity of the anaphase-promoting complex/cyclosome (APC/C), an E3 ubiquitin ligase. APC/C functions with the assistance of the adapter protein Cdc20 and the E2 ubiquitin-conjugating enzyme UbcH10 for orderly progression of mitosis. Reportedly, deregulated expression of either CDC20 or UBCH10 is associated with increased tumor aggressiveness in various human malignancies, including head and neck squamous cell carcinoma (HNSC). Previously, our laboratory reported that Cdc20 transcriptionally activates UBCH10 expression in cultured HNSC cells. This led us to investigate their correlated expression in primary HNSC malignancies in a prospective Eastern Indian study cohort and The Cancer Genome Atlas (TCGA) dataset. Quantitative PCR and immunohistochemistry analyses were performed to assess CDC20 and UBCH10 expression in primary HNSC patient samples of a prospective Eastern-Indian cohort. The RNA-sequencing data were retrieved from TCGA-head and neck squamous cell carcinoma (HNSC) cohort. Additionally, FISH assay was carried out to investigate cellular ploidy status in HNSC tumor and adjacent normal samples, as well as in cultured HNSC cells and validated in silico in TCGA cohorts. Assays to evaluate proliferation, migration and invasion of HNSC cells were conducted under the influence of correlated expression of CDC20 and UBCH10. Kaplan–Meier analyses was performed to determine the impact of survival outcome under the influence of correlated CDC20-UBCH10 expression. The initial results revealed correlated overexpression of both genes in a significant number of primary HNSC samples from the prospective cohort. Concordantly, gene expression data from the TCGA-HNSC cohort revealed a similar correlation. In addition, HNSC-affected individuals with this correlated overexpression showed an increased level of cellular aneuploidy. More importantly, Kaplan‒Meier analyses revealed that patients harboring this correlated expression signature had the poorest survival outcome. Findings of exacerbation in proliferation, migration and invasion properties of cultured HNSC cells, under the influence of concerted overexpression of CDC20-UBCH10, further corroborated our findings. Further investigations revealed that this expression signature occurs in several other malignancies of solid tissues and negatively influences their survival outcomes. Together, these findings delineate the correlation of CDC20-UBCH10 overexpression with survival outcomes in patients with primary HNSC and other solid tumors and suggest the potential of this expression signature for prognostication. The online version contains supplementary material available at 10.1186/s12885-025-14773-x.
- 30 September 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1)
Open AccessA signature of correlated CDC20 and UBCH10 expression indicates poor prognosis in primary head and neck squamous cell carcinoma
The orchestration of mitotic checkpoint execution depends on the enzymatic activity of the anaphase-promoting complex/cyclosome (APC/C), an E3 ubiquitin ligase. APC/C functions with the assistance of the adapter protein Cdc20 and the E2 ubiquitin-conjugating enzyme UbcH10 for orderly progression of mitosis. Reportedly, deregulated expression of either CDC20 or UBCH10 is associated with increased tumor aggressiveness in various human malignancies, including head and neck squamous cell carcinoma (HNSC). Previously, our laboratory reported that Cdc20 transcriptionally activates UBCH10 expression in cultured HNSC cells. This led us to investigate their correlated expression in primary HNSC malignancies in a prospective Eastern Indian study cohort and The Cancer Genome Atlas (TCGA) dataset. Quantitative PCR and immunohistochemistry analyses were performed to assess CDC20 and UBCH10 expression in primary HNSC patient samples of a prospective Eastern-Indian cohort. The RNA-sequencing data were retrieved from TCGA-head and neck squamous cell carcinoma (HNSC) cohort. Additionally, FISH assay was carried out to investigate cellular ploidy status in HNSC tumor and adjacent normal samples, as well as in cultured HNSC cells and validated in silico in TCGA cohorts. Assays to evaluate proliferation, migration and invasion of HNSC cells were conducted under the influence of correlated expression of CDC20 and UBCH10. Kaplan–Meier analyses was performed to determine the impact of survival outcome under the influence of correlated CDC20-UBCH10 expression. The initial results revealed correlated overexpression of both genes in a significant number of primary HNSC samples from the prospective cohort. Concordantly, gene expression data from the TCGA-HNSC cohort revealed a similar correlation. In addition, HNSC-affected individuals with this correlated overexpression showed an increased level of cellular aneuploidy. More importantly, Kaplan‒Meier analyses revealed that patients harboring this correlated expression signature had the poorest survival outcome. Findings of exacerbation in proliferation, migration and invasion properties of cultured HNSC cells, under the influence of concerted overexpression of CDC20-UBCH10, further corroborated our findings. Further investigations revealed that this expression signature occurs in several other malignancies of solid tissues and negatively influences their survival outcomes. Together, these findings delineate the correlation of CDC20-UBCH10 overexpression with survival outcomes in patients with primary HNSC and other solid tumors and suggest the potential of this expression signature for prognostication. The online version contains supplementary material available at 10.1186/s12885-025-14773-x.
- Open Access
- 8 September 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (10) , 110695
Tubulin hyperacetylation drives HMGB1 nuclear exit via the ROS-PARP1 axis, leading to rotenone-induced G2/M arrest
- 8 September 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (10) , 110695
Open AccessTubulin hyperacetylation drives HMGB1 nuclear exit via the ROS-PARP1 axis, leading to rotenone-induced G2/M arrest
- Open Access
Tubulin hyperacetylation drives HMGB1 nuclear exit via the ROS-PARP1 axis leading to rotenone-induced G2/M Arrest
Rotenone, a lipophilic pesticide, is strongly linked to dopaminergic neuronal loss in Parkinson’s disease (PD), primarily through mitochondrial complex I inhibition. While rotenone induces G2/M arrest in dividing cells, the underlying molecular events remain unclear. We identify HMGB1 as a key player in this process. HMGB1, known for its roles in genomic integrity and inflammation, exits the nucleus during rotenone-induced G2/M arrest, whereas its nuclear retention protects against mitotic DNA damage. We further reveal that tubulin hyperacetylation precedes HMGB1 nuclear release. Notably, reducing tubulin acetyltransferase lowers mitochondrial ROS (mtROS), preventing HMGB1 nuclear exit and mitotic DNA damage. Additionally, inhibiting PARP1 hyperactivation with PJ34 blocks HMGB1 exit and prevents G2/M arrest. These findings suggest that ROS-induced DNA damage elevates PARP1 activity, promoting HMGB1 nuclear exit and interfering with DNA repair. This tubulin acetylation/mtROS/HMGB1 axis may underlie rotenone-induced neurotoxicity, contributing to dopaminergic neuron vulnerability in PD and offering potential neuroprotective targets.
Open AccessTubulin hyperacetylation drives HMGB1 nuclear exit via the ROS-PARP1 axis leading to rotenone-induced G2/M Arrest
Rotenone, a lipophilic pesticide, is strongly linked to dopaminergic neuronal loss in Parkinson’s disease (PD), primarily through mitochondrial complex I inhibition. While rotenone induces G2/M arrest in dividing cells, the underlying molecular events remain unclear. We identify HMGB1 as a key player in this process. HMGB1, known for its roles in genomic integrity and inflammation, exits the nucleus during rotenone-induced G2/M arrest, whereas its nuclear retention protects against mitotic DNA damage. We further reveal that tubulin hyperacetylation precedes HMGB1 nuclear release. Notably, reducing tubulin acetyltransferase lowers mitochondrial ROS (mtROS), preventing HMGB1 nuclear exit and mitotic DNA damage. Additionally, inhibiting PARP1 hyperactivation with PJ34 blocks HMGB1 exit and prevents G2/M arrest. These findings suggest that ROS-induced DNA damage elevates PARP1 activity, promoting HMGB1 nuclear exit and interfering with DNA repair. This tubulin acetylation/mtROS/HMGB1 axis may underlie rotenone-induced neurotoxicity, contributing to dopaminergic neuron vulnerability in PD and offering potential neuroprotective targets.
- Open Access
- 24 September 2024
- Published by AccScience Publishing in Gene & Protein in Disease
- p. 3928
Genetic association of regulatory single nucleotide variants in GSTA1 and SULT1A1 with cigarette smoke-related lung cancer in an eastern Indian population
The differential expression of genes involved in xenobiotic metabolism and DNA repair has been implicated in the etiology of cigarette smoke-related lung cancer. Our research group has previously identified 22 gene expression-correlated DNAse hypersensitive sequence-single nucleotide variants (SNVs) with regulatory potential to modulate the transcription of seven xenobiotic metabolisms and seven DNA repair genes, thereby contributing to individual susceptibility to lung cancer. In this study, we evaluated the genetic association between lung cancer and two regulatory SNVs (rSNVs) from the list of 22, namely, rs2207950 (A/G) and rs743590 (G/A), which modulate the expression of the xenobiotic metabolism genes GSTA1 and SULT1A1, respectively. A polymerase chain reaction-restriction fragment length polymorphism-based association study was conducted among lung cancer patients exposed to cigarette smoke and healthy smoker controls from an eastern Indian population. A risk genotype AA of GSTA1 rs2207950, with predictive potential, was significantly over-represented among the patients. This genotype is known to cause lower expression of GSTA1 compared to the other two genotypes, potentially leading to reduced efficiency in clearing cigarette smoke-associated xenobiotics, thereby contributing to lung cancer development. Identifying such rSNVs in specific populations can contribute to the development of tailored therapies based on precision medicine, as well as inform efficient legislation governing tobacco use and genetic counseling.
- 24 September 2024
- Published by AccScience Publishing in Gene & Protein in Disease
- p. 3928
Open AccessGenetic association of regulatory single nucleotide variants in GSTA1 and SULT1A1 with cigarette smoke-related lung cancer in an eastern Indian population
The differential expression of genes involved in xenobiotic metabolism and DNA repair has been implicated in the etiology of cigarette smoke-related lung cancer. Our research group has previously identified 22 gene expression-correlated DNAse hypersensitive sequence-single nucleotide variants (SNVs) with regulatory potential to modulate the transcription of seven xenobiotic metabolisms and seven DNA repair genes, thereby contributing to individual susceptibility to lung cancer. In this study, we evaluated the genetic association between lung cancer and two regulatory SNVs (rSNVs) from the list of 22, namely, rs2207950 (A/G) and rs743590 (G/A), which modulate the expression of the xenobiotic metabolism genes GSTA1 and SULT1A1, respectively. A polymerase chain reaction-restriction fragment length polymorphism-based association study was conducted among lung cancer patients exposed to cigarette smoke and healthy smoker controls from an eastern Indian population. A risk genotype AA of GSTA1 rs2207950, with predictive potential, was significantly over-represented among the patients. This genotype is known to cause lower expression of GSTA1 compared to the other two genotypes, potentially leading to reduced efficiency in clearing cigarette smoke-associated xenobiotics, thereby contributing to lung cancer development. Identifying such rSNVs in specific populations can contribute to the development of tailored therapies based on precision medicine, as well as inform efficient legislation governing tobacco use and genetic counseling.
- Open Access
Estrogen receptor alpha (ERα) driven trans-regulation of mitotic checkpoint complex (MCC) components affects the clinical outcome of breast cancer
Hormone receptors (HR), namely estrogen receptor (ER) and progesterone receptor (PR), are prevalent in most malignant tumors. Although previous literature provided clues for ERα in regulating mitosis and ploidy status in breast cancer (BC) cells, reports on the mitotic regulators being the targets of HR are sparse. To delve deeper into ERα’s impact on mitotic execution, our study focuses on examining its transcriptional activity on the core mitotic checkpoint complex (MCC) components, which are involved in ploidy maintenance. The expression of the core MCC components (Bub3, Mad2, and BubR1) was analyzed by quantitative-PCR and immunohistochemistry in breast tumors and adjacent normal tissues from the cancer genome atlas-breast invasive carcinoma collection (TCGA BRCA) dataset and in a prospective cohort of Eastern Indian breast cancer affected individuals. The preliminary data from these cohorts indicated an influence of ERα on the two MCC components, namely Mad2 and BubR1. Subsequently, luciferase reporter assays and chromatin immunoprecipitation were performed which revealed that ERα promotes transcriptional activation of MAD2 and BUB1B through direct recruitment on these promoters, showing affects in mitotic outcome. Interestingly, the ectopic introduction of ERα, in an HR-ve breast cancer line, MDA-MB-231, significantly reduced the percent aneuploidy. Moreover, we found that overexpression of MAD2 and BUB1B is associated with poorer survival in HR-positive (HR+ve) patients in both cohorts. Our findings provide insights into the specific role of ERα-mediated transcriptional regulation of mitosis and ploidy outcome. Targeting the deregulated MCC components thus offers translational potential for the therapeutic management of breast cancer.
Open AccessEstrogen receptor alpha (ERα) driven trans-regulation of mitotic checkpoint complex (MCC) components affects the clinical outcome of breast cancer
Hormone receptors (HR), namely estrogen receptor (ER) and progesterone receptor (PR), are prevalent in most malignant tumors. Although previous literature provided clues for ERα in regulating mitosis and ploidy status in breast cancer (BC) cells, reports on the mitotic regulators being the targets of HR are sparse. To delve deeper into ERα’s impact on mitotic execution, our study focuses on examining its transcriptional activity on the core mitotic checkpoint complex (MCC) components, which are involved in ploidy maintenance. The expression of the core MCC components (Bub3, Mad2, and BubR1) was analyzed by quantitative-PCR and immunohistochemistry in breast tumors and adjacent normal tissues from the cancer genome atlas-breast invasive carcinoma collection (TCGA BRCA) dataset and in a prospective cohort of Eastern Indian breast cancer affected individuals. The preliminary data from these cohorts indicated an influence of ERα on the two MCC components, namely Mad2 and BubR1. Subsequently, luciferase reporter assays and chromatin immunoprecipitation were performed which revealed that ERα promotes transcriptional activation of MAD2 and BUB1B through direct recruitment on these promoters, showing affects in mitotic outcome. Interestingly, the ectopic introduction of ERα, in an HR-ve breast cancer line, MDA-MB-231, significantly reduced the percent aneuploidy. Moreover, we found that overexpression of MAD2 and BUB1B is associated with poorer survival in HR-positive (HR+ve) patients in both cohorts. Our findings provide insights into the specific role of ERα-mediated transcriptional regulation of mitosis and ploidy outcome. Targeting the deregulated MCC components thus offers translational potential for the therapeutic management of breast cancer.
- Open Access
- 22 September 2023
- Published by Springer Nature in Cell Death & Disease
- Vol. 14 (9) , 1-15
FBXW2 suppresses breast tumorigenesis by targeting AKT-Moesin-SKP2 axis
Oncogene Moesin plays critical role in initiation, progression, and metastasis of multiple cancers. It exerts oncogenic activity due to its high-level expression as well as posttranslational modification in cancer. However, factors responsible for its high-level expression remain elusive. In this study, we identified positive as well as negative regulators of Moesin. Our study reveals that Moesin is a cellular target of F-box protein FBXW2. We showed that FBXW2 suppresses breast cancer progression through directing proteasomal degradation of Moesin. In contrast, AKT kinase plays an important role in oncogenic function of Moesin by protecting it from FBXW2-mediated proteasomal degradation. Mechanistically, AKT phosphorylates Moesin at Thr-558 and thereby prevents its degradation by FBXW2 via weakening the association between FBXW2 and Moesin. Further, accumulated Moesin prevents FBXW2-mediated degradation of oncogene SKP2, showing that Moesin functions as an upstream regulator of oncogene SKP2. In turn, SKP2 stabilizes Moesin by directing its non-degradable form of polyubiquitination and therefore AKT-Moesin-SKP2 oncogenic axis plays crucial role in breast cancer progression. Collectively, our study reveals that FBXW2 functions as a tumor suppressor in breast cancer by restricting AKT-Moesin-SKP2 axis. Thus, AKT-Moesin-SKP2 axis may be explored for the development of therapeutics for cancer treatment.
- 22 September 2023
- Published by Springer Nature in Cell Death & Disease
- Vol. 14 (9) , 1-15
Open AccessFBXW2 suppresses breast tumorigenesis by targeting AKT-Moesin-SKP2 axis
Oncogene Moesin plays critical role in initiation, progression, and metastasis of multiple cancers. It exerts oncogenic activity due to its high-level expression as well as posttranslational modification in cancer. However, factors responsible for its high-level expression remain elusive. In this study, we identified positive as well as negative regulators of Moesin. Our study reveals that Moesin is a cellular target of F-box protein FBXW2. We showed that FBXW2 suppresses breast cancer progression through directing proteasomal degradation of Moesin. In contrast, AKT kinase plays an important role in oncogenic function of Moesin by protecting it from FBXW2-mediated proteasomal degradation. Mechanistically, AKT phosphorylates Moesin at Thr-558 and thereby prevents its degradation by FBXW2 via weakening the association between FBXW2 and Moesin. Further, accumulated Moesin prevents FBXW2-mediated degradation of oncogene SKP2, showing that Moesin functions as an upstream regulator of oncogene SKP2. In turn, SKP2 stabilizes Moesin by directing its non-degradable form of polyubiquitination and therefore AKT-Moesin-SKP2 oncogenic axis plays crucial role in breast cancer progression. Collectively, our study reveals that FBXW2 functions as a tumor suppressor in breast cancer by restricting AKT-Moesin-SKP2 axis. Thus, AKT-Moesin-SKP2 axis may be explored for the development of therapeutics for cancer treatment.
- Open Access
- 30 August 2023
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 14, 1264772
Editorial: Genetic regulation of mitosis and ploidy in cancer
Editorial: Genetic regulation of mitosis and ploidy in cancer
- 30 August 2023
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 14, 1264772
Open AccessEditorial: Genetic regulation of mitosis and ploidy in cancer
Editorial: Genetic regulation of mitosis and ploidy in cancer